ERBB2 and gastric cancer: Lapatinib, an anti-HER2 tyrosine kinase inhibitor, also failed to show improved OS as a first-line treatment in combination with capecitabine and oxaliplatin in patients with HER2-positive metastatic GC, esophageal, or gastroesophageal adenocarcinoma [11].